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Background: There are many drugs recommended for pain relief in patients with migraine headache.
Methods: In a prospective double blind randomized clinical trial, 90 patients (age≥ 18) presenting to Emergency
medicine Department with Migraine headache were enrolled in two equal groups. We used intravenous propofol
(10 mg every 5–10 minutes to a maximum of 80 mg, slowly) and intravenous dexamethasone (0.15 mg/kg to a
maximum of 16 mg, slowly), in group I and II, respectively. Pain explained by patients, based on VAS (Visual
Analogue Scale) was recorded at the time of entrance to ED, and after injection. Data were analyzed by paired
samples t test, using SPSS 16. P < 0.05 was considered to be statistically significant.
Results: The mean of reported pain (VAS) was 8 ± 1.52 in propofol group and 8.11 ± 1.31 in dexamethasone group
at presenting time (P > 0.05). The VAS in propofol group was obviously decreased to 3.08 ± 1.7, 1.87 ± 1.28 and
1.44 ± 1.63 after 10, 20 and 30 minutes of drug injection, respectively. The VAS in dexamethasone group was
5.13 ± 1.47, 3.73 ± 1.81 and 3.06 ± 2 after 10, 20 and 30 minutes of drug injection, respectively. The mean of reported
VAS in propofol group was less than dexamethasone group at the above mentioned times (P < 0.05). The reduction
of headache in propofol group, also, was very faster than dexamethasone group (P < 0.05). There were no adverse
side effects due to administration of both drugs.
Conclusions: Intravenous propofol is an efficacious and safe treatment for patients presenting with Migraine
headache to the emergency department.
Trial registration: Clinical Trials IRCT201008122496N4
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Headache is one of the common complaints more fre-
quent than common cold. It allocates almost 3 million vis-
its to the Emergency Department (ED) in the United
States. Most of patients presenting with headache have be-
nign headaches that need symptomatic treatments [1]. Mi-
graine typically starts in the 2nd decade of life, reaches its
peak in the middle age, and its prevalence among women* Correspondence: soleimanpourh@tbzmed.ac.ir
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distribution, and reproduction in any medium(18%) is more than among men (6%) [2,3]. The lifetime
prevalence of migraine is at least 18% [4]. In a study car-
ried out on 405 patients with primary chronic headache, it
was revealed that 95% of the patients complained of ten-
sion type headache and only 4% of them suffered from
chronic migraine headache [5].
The International Headache Society (IHS) has defined
the migraine headache criteria related to the migraine
headache as following:
A. At least five attacks fulfilling criteria in B, C, D, and E.
B. Attack lasts 4 to 72 hours with or without treatment.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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3. Moderate to severe intensity
4. Aggravated by walking up stairs or similar routine
physical activity
D. During headache, at least one of the following:
1. Nausea or vomiting (or both)
2. Photophobia and phonophobia
E. History, physical and neurologic examination and,
if appropriate, diagnostic tests to exclude related
organic disease [1]
This society (IHS) has introduced acetaminophen and
NSAIDs for mild to moderate cases of migraine and in
more severe or refractory and status cases selective re-
ceptor agonists 5HT (triptans category) and steroids
have been introduced [6,7]. In some studies, there has
been a 49% relapse after migraine treatment leading to
exacerbation of anxiety in patients in EDs [8,9].
A new drug that few studies have been carried out
regarding its role in relieving migraine headaches is pro-
pofol (2 and 6 di- isopropyl phenol). Its pharmacological
mechanisms are related to its agonist characteristics on
gamma-amino butyric acid (GABA) receptors [10]. The
drug also inhibits the afferent sympathetic activity and
reduces reflex sensitivity of the cardiac baroreceptor re-
flex [11]. Propofol can also cause vasodilatation by
stimulating production of nitric oxide (NO) [12].
In this study we tried to investigate the role and effect
of intravenous administration of propofol in migraine
headache relief compared with one of the other current
treatments (intravenous dexamethasone) in patients
who presented to ED of Imam Reza teaching hospital in
Tabriz, Iran.
Methods
A clinical trial study was performed in the ED of Imam
Reza teaching hospital, Iran [13]. Based on existing stud-
ies and articles, and in particular with regards to the
results obtained from the study of Krusz and colleagues
reporting a 95% efficacy of propofol in the treatment of
migraine headache [10], 38 samples of each group were
determined considering α= 0.05, p =%95 and d = 0.06
that 45 samples for each group were examined and
determined to increase validity of the study. Therefore,
the study population was considered 90 people (age ≥
18). First patients who were complaining of headaches
were detected, and then history was taken and complete
examination (general and neurologic examination) of thepatients was performed. So that based on IHS criteria
migraine diagnosis has been established [1]. The full trial
design is summarized in Figure 1.
Patients with the following conditions were excluded:
– History of receiving opioid compounds or other
triptans such as vasoconstrictors like
dihydroergotamine 24 hours before referring to the
emergency.
– Patients treated with systemic corticosteroids
– Allergy to propofol and dexamethasone, or eggs and
soy.
– Patients with a history of Diabetic Mellitus, active
peptic ulcers, Myocardial Infarction within the last
week and familial hypokalemic periodic paralysis (for
dexamethasone).
This study was approved by Ethics Committee of “Tabriz
University of Medical Sciences”. However, all aspects of the
present study plan were explained to patients and then we
obtained their written consent.
Patients were randomly divided into two equal sub-
groups I and II each with 45 people by picking a ballot.
Group I received propofol and group II received dexa-
methasone. Variables examined in the study were: head-
ache intensity based on VAS value criteria, before
treatment and at 5, 10, 20, 30 and 45 minutes after treat-
ment, age and sex.
Using a graded page that was numbered from 0 to 10;
the patients were asked to mark the page based on the pain
they tolerated in which 0 is the sign of analgesia and 10 is
the sign of the most severe pain. Patient's vital signs and
other signs such as nausea, vomiting, photophobia, phono-
phobia were recorded. After establishing intravenous line,
patients were connected to cardiac monitors, automated
blood pressure monitors, pulse-oximeters and capnogra-
phy monitors. Another specialist who was blinded to all
procedures of the study filled out the questionnaires and
performed the injections. All injections were performed on
the left hand of the patients. To blind the injection per-
former to the type of injection, a curtain separating the
hands and upper body of the patient from the lower part
was utilized to prevent the performer from distinguishing
the injection site (the curtain was attached to two tall verti-
cal stands lying on both sides of the patient).
Patients were blinded to the injected medications as
well. In group I propofol (LIPURO-B.BRAUN) 1% was
injected intravenously every 5 to 10 minutes with bolus
dose of 10 mg (maximum dose of 80 mg) slowly (at the
rate of 1 mL over 10 seconds), until pain was maximally
relieved (VAS ≤ 2) [1].
With the same method in Krusz’s study, the treat-
ment response appeared at 50 mg minimally and at
90 eligible consenting 
participants 
Excluded  (n=0   ) 
Not meeting inclusion criteria (n=0  ) 
Declined to participate (n=0  ) 
Other reasons (n=0  ) 
Analysed  (n=45  ) 
Patients be followed up at 5, 10, 20, 30 and 
45 minutes after initiation of treatment 
Lost to follow-up (give reasons) (n=0  ) 
Discontinued intervention (give reasons) (n=0  ) 
Group I received propofol  (n= 45 
) 
Received allocated intervention (n=45  )
Did not receive allocated intervention 
(give reasons) (n=0  )
Patients be followed up at 5, 10, 20, 30 and 
45 minutes after initiation of treatment 
Lost to follow-up (give reasons) (n=0  )
Discontinued intervention (give reasons) (n=0  )
Group II received dexamethasone  
(n=45  ) 
Received allocated intervention (n=45  )
Did not receive allocated intervention (give 
reasons) (n=0  )
Analysed  (n=45  ) 
Randomized (n= 90 ) 
Figure 1 CONSORT 2010 Flow Diagram of trial design.
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tion site 1 mL of Lidocaine 2% per 10 mL of propofol
was added. It has already been identified that giving
such a dose of lidocaine (1 mL of lidocaine 2%) even as
intravenous bolus has no effect on reducing headache
[9]. In group II intravenous dexamethasone (Decardol)
4 mg/ml with dose of 0.15 mg/kg (maximum dose of
16 mg) was injected, slowly (at the rate of 1 mL over
10 seconds).
Based on VAS scaling, level of headache, 5, 10, 20, 30
and 45 minutes after initiation of treatment was
recorded in patients. When no improvement in pain of
each of two groups was observed, common medications
such as opioids and NSAIDs were used.
Data obtained from the study were statistically ana-
lyzed by descriptive statistics (mean ± SD), analysis of
variance and repeated measures (Repeated Measure-
ment) and statistical software SPSS 16. In this study,
P values less than 0.05 was considered significant.
Results
The mean age of patients treated with dexamethasone
was 36.27 ± 13.38 and in group treated with intravenouspropofol was 35.65 ± 12.55 years. Independent T-test
results showed no significant difference in terms of aver-
age age in the two study groups (P = 0.832).
In dexamethasone-treated group there were 28 females
(62.22%) and 17 males (37.77%) and in the propofol-
treated group there were 30 females (66.6%) and 15
males (33.3%). Chi-square test results showed no signifi-
cant difference in terms of gender distribution in the
two study groups (p = 0.577).
Considering associated symptoms, the findings of this
study are as follows:
1. Nausea: most common symptom associated with
both groups of patients with headache was nausea.
The prevalence of nausea in the group treated with
dexamethasone and propofol-treated group was
95.55% and 93.33% respectively.
2. Vomiting: Seventeen patients in the group treated
with dexamethasone (37.77%) and 18 cases of
patients treated with propofol group (40%) had this
accompanying symptom.
3. Photophobia: Fourteen cases of patients in the group
treated with dexamethasone (31.11%) and 17 cases of
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complained of photophobia.
4. Phonophobia: Nine patients in the group treated
with dexamethasone (20%) and eight cases of
patients treated with propofol group (17.77%)
complained of this symptom.
Chi-square test results showed no significant difference
(P > 0.05) on the prevalence of the above-mentioned
symptoms in groups under study.
Average pain in the group treated with dexamethasone
prior to the desired intervention was 8.11 ± 1.31 and it
was 8 ± 1.52 in groups treated with propofol. The inde-
pendent T-test results showed no significant difference
in terms of pain severity in both groups on arrival and
before any therapeutic intervention (P = 0.712).
Pain level was compared in patients using the VAS
method in times of entering the study and at 5, 10, 20,
30 and 45 minutes after intervention in both groups
who were treated with dexamethasone and propofol.
Table 1 compares the level of pain reduction at differ-
ent times after treatment interventions in the groups
treated with dexamethasone and propofol. As it can be
seen, level of pain reduction has significantly decreased
more at all times in patients treated with propofol
(P < 0.001).
Although comparing intra-group pain level mean
within different times revealed that the pain level
decreased from 8 to 1.8 in minute 20 in groups treated
with propofol, the group treated with dexamethasone
never improved to this extent.
In addition to evaluated and compared pain level at
different times in the two study groups, pain reduction
was assigned in every individual group over time and the
level of their significance was evaluated. Findings of this
comparison are given in Tables 2 and 3. Pain reduction
was higher than other times in the first 5 minutes and
the rate of pain reduction decreased over time.
Based on the findings contained in Table 2, as can be
seen pain reduction in patients treated with propofol in
the first 5 minutes is also more than other times. In this
group, pain reduction in 2nd five minutes is high as well.
Like the group treated with dexamethasone, pain reduc-
tion decreased over time. The difference is that pain re-
duction was in a higher rate in this group.
Comparing the rate of treatment response in both
groups, as can be seen in Table 1, in groups treated withTable 1 Comparing the rate of treatment response between t
At presenting time Minute 5
VAS in Group I (Propofol) 8 ± 1.52 5.46 ± 1.56
VAS in Group II (Dexamethasone) 8.11 ± 1.31 6.57 ± 1.57
P Value 0.712 0.001propofol in 10 minutes, revealed that pain level mean
decreased from 8 to 3.08. Whereas in the dexametha-
sone treated group, 30 minutes were needed for the pain
level mean to reach the above mentioned number. Al-
though no significant difference was observed in terms
of pain level mean after 20 minutes, mean pain was al-
ways lower in propofol treated group.
In this study, the parameter of good response to treat-
ment is considered as VAS ≤ 2 [1]. Accordingly, in none
of the defined periods was there significant difference in
terms of response to treatment between males and
females in both groups treated with propofol and dexa-
methasone (P > 0.05).
Over time, in the tenth minute in patients treated with
propofol, the response to treatment was considerably
high (40% comparing with 2% in patients treated with
dexamethasone). The highest rate of response in the
group treated with dexamethasone was in minute 30
(51%) and in propofol treated group at minute 20 (66%).
Mean blood pressure, heart rate and O2 Saturation of
patients were compared in defined times in both groups
and there was no significant difference. Then the
patients were followed up in the hospital until they were
discharged as following: In 20 cases of patients treated
with propofol (44.4%) mild sedation was observed as a
complication. Also, slurred speech was reported in one
patient and in two cases mild decline in arterial oxygen
saturation (O2 Saturation = 89%) was reported which was
quickly resolved with nasal oxygen administration.Discussion
Since migraine is a prevalent disease, several studies
have been carried out in the world on how to treat se-
vere migraine headaches in patients referred to emer-
gency departments. A study concluded that the
treatment of refractory migraine requires aggressive
intravenous treatment [14]. In a recent study on the
health care cost in the patients with migraine headache,
it was suggested that 45% of the patients with migraine
headache do not receive appropriate treatment. Total
health care cost tends to be higher in these patients due
to their frequent out-patient and emergency referrals
compared to the ones receiving medications regularly,
even expensive anti-migraine agents [15].
Although many researches have been carried out on
the effectiveness of propofol pain relief after surgery, fewwo groups
Minute 10 Minute 20 Minute 30 Minute 45
3.08 ± 1.7 1.87 ± 1.28 1.44 ± 1.63 1.16 ± 1.55
5.13 ± 1.47 3.73 ± 1.81 3.06 ± 2 2.87 ± 1.81
<0.001 <0.001 <0.001 <0.001
Table 2 The average of pain reduction at different times in patients received Propofol
The pain score in. . . The average of pain reduction in group I P Value
Minute 5 comparing with presenting time 2.53 ± 1.34 <0.001
Minute 10 comparing with minute 5 2.37 ± 1.41 <0.001
Minute 20 comparing with minute 10 1.41 ± 1.48 <0.001
Minute 30 comparing with minute 20 0.827± 1.25 0.001
Minute 45 comparing with minute 30 0.375± 0.646 0.009
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cacy in relieving pain in the emergency department.
As mentioned in results, the study groups were identi-
cal and based on VAS scoring criteria had no significant
difference regarding age, sex and pain level. Although
both dexamethasone and propofol are effective in reliev-
ing headache over time, propofol is more effective than
dexamethasone and at different times, pain reduction is
significantly higher in propofol treated patients than
patients treated with dexamethasone.
Many studies have discussed the efficacy of dexa-
methasone. In most of the studies it is noted that dexa-
methasone, especially in combination with other drugs,
has considerable effect on migraine. The findings of this
study, like most studies, confirm this. But some studies
have rejected the efficacy of dexamethasone [16] and
others have reported it to be beneficial in the treatment
of migraine by adding it to other common drugs [17-19].
Friedman and his colleagues compared dexamethasone
with placebo. They showed that there was no significant
difference between the two groups at first hour regard-
ing pain reduction (P = 0.03) and they did not recom-
mend routine use of intravenous dexamethasone [20].
Other studies have been carried out on the role of dexa-
methasone in the relapse rate of migraine headache.
Some of these studies have shown that dexamethasone
reduces migraine relapse in patients [21]. A study also
showed that dexamethasone reduced relapse by 50% and
compared with NSAIDs and triptans, in addition to con-
trolling it also reduces relapse of headache intensity [22].
Other studies have emphasized on the effective role of
dexamethasone in reducing recurrent migraines [23,24].
However, some have questioned it and despite the find-
ings of this study considered it an ineffective drug [25].
Unlike dexamethasone, few studies have been con-
ducted on the role of propofol, the most commonTable 3 The average of pain reduction at different times in p
The pain score in. . . The av
Minute 5 comparing with presenting time
Minute 10 comparing with minute 5
Minute 20 comparing with minute 10
Minute 30 comparing with minute 20
Minute 45 comparing with minute 30medication used in anesthesia induction in operating
room, in the treatment of migraine headache [26,27].
In 2002 two cases of migraine were reported to be
treated by intravenous propofol in which the headache
scoring of the first and the second patients dropped
from 100/100 to 10/100 and from 92/100 to 40/100 re-
spectively [28].
In another study of ours carried out on 8 patients with
refractory migraine, propofol administration significantly
reduced migraine headache in the patients [29]. In the
current study, the average rate of pain score according
to VAS reduced from 8/10 to 1/10. On the other hand
in the present study, rate of pain reduction has been
considered by researchers. Comparing the treatment re-
sponse rate in both groups, the average pain level in pro-
pofol group declined from 8 to 3.08 in the tenth minute.
While in the dexamethasone group, after 30 minutes,
the average pain level reached the above-mentioned
number. Therefore, the treatment response rate was
considerably higher in the propofol treated group. Other
reports have been published on the use of intravenous
propofol at sub-hypnotic dose for refractory migraine
[30].
As mentioned before, rate of response to treatment
in this study was defined and evaluated as VAS ≤ 2. The
highest rates of response to treatment were recorded in
the 10th and 20th minutes by both drugs. The differ-
ence was that the rate of response to treatment in these
times was considerably higher in the propofol treated
group.
Like our findings, results of another study that is the
largest study on the role of propofol in the treatment of
headache showed that 82% of 77 patients with severe
headache (between 7–10) who were scored with VAS,
were completely pain-relieved and in the rest of them
pain declined by 50 to 90 percent [10]. Another studyatients received Dexamethasone
erage of pain reduction in group II P Value
1.53 ± 1.07 <0.001
1.44 ± 1.25 <0.001
1.4 ± 1.37 <0.001
0.177± 3.02 0.695
0.45 ± 0.782 0.001
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chronic daily headache [31].
In most of studies, the main reason of propofol’s re-
markable effect is reported as the high tendency of pro-
pofol to GABA receptors that are in low functional
status in this disease so that propofol overcomes them
through stimulating in this physiological process.
Researchers have asserted that using other drugs with
this property (excitatory GABA receptors) as potential
drugs to treat migraine and other headaches, requires
further investigation [11].
It seems that propofol plays its therapeutic role affect-
ing chlorine channels in β1 subunits of GABA receptors
[29,32]. Medication Overuse Headache (MOH) is a term
frequently used in association with chronic migraine; it
however can be used in cases with over usage of all
medications used for headache treatment as well [33].
Propofol not only, similar to all other medications, might
cause MOH but also could be considered an effective treat-
ment of MOH. Therefore, further studies focusing on the
comparison of the probable therapeutic effects of propofol
and other conventional medications including Topiramate
and onabotulinumtoxinA are required to be conducted.
Limitations
Similar to most of ED trials, our sampling was conveni-
ence; therefore we might have had an unrecognized se-
lection bias. In addition, we did not select a standard
abortive treatment as different drug combinations are
often required and not all patients do respond to a
standard regimen.
Although all patients were discharged after pain was
relieved, we did not follow up the patients in days after
being discharged from ED. However, one of the merits
of IV Propofol and Dexamethasone is that their effect
may be prolonged, even after a single bolus administra-
tion. Patients may get hours, days or weeks of relief. It
seems necessary to evaluate the patients in the following
days, as the question of whether the pain relief period is
extended after discharge still remains. If so, then for
how many days would this period last?
Furthermore we did not assess and compare the rate
of relapse in both groups.
Our study shows that dexamethasone and specially
propofol are useful in the acute migraine headache but
does not tell us whether they decrease recurrent head-
ache. And also we have no data on several abortive
agents; we cannot draw any conclusion on which is the
most effective regarding the relief of acute headache.
Another limitation of our study was to administer
titrated doses of propofol whereas dexamethasone was
administered in bolus form. This was due to the fact that
there is no medication effective in migraine treatment
used titrated intravenously so that it could be comparedas a conventional treatment with propofol. Furthermore,
common intravenous treatments for migraine including
NSAIDs and sumatriptan are not available in our coun-
try; therefore, propofol was selected to be compared
with dexamethasone.
Although our study suggested propofol as a new and
effective treatment which may improve the quality of life
and have productivity benefits to this therapy, we did
not perform a formal economic analysis demonstrating
these benefits.
All above-mentioned items are areas requiring further
investigations in the future.
Conclusion
According to findings of this study, the speed and rate
of response to migraine headache treatment is consider-
ably higher using propofol than dexamethasone and pain
relief in patients treated with propofol improves more
quickly based on the VAS. This drug has also no consid-
erable side effect and can therefore be administered as
an effective medication with low side effect and good
availability to treat migraine headaches.
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